Oxygen is very important for energy metabolism, which drives cellular bioenergetics throughout our body. Precisely distributed vasculature aids in delivering oxygenated blood to all body tissues. Regions of low oxygen levels are generally termed as ‘hypoxic regions’. Hypoxia is profound in various solid tumors, as well as in myocardial infarction, some chronic renal diseases and gliomas. Rapid proliferation of a tumorous mass prevents vascularization in time, in turn leading to hypoxia in solid tumors. Low oxygen tension in tumors is found to be responsible for increased metastasis, poor patient survival, as well as drug resistance in breast cancers, as well as in cases of squamous tumors of the head and neck or cervix. Recent years have seen great progress in understanding tumor biology and of the surrounding microenvironment. Solid tumors that create regions with low oxygen levels are generally termed as being hypoxic. The creation of these hypoxic regions offer a tremendous opportunity to develop targeted therapies which can take advantage of this. Hypoxia is not merely a random by-product of cells due to uncontrolled tumor growth, rather it is a constantly evolving participant in overall tumor growth and fate.
This special issue will invite submissions which describe current trends and recent advances in drug therapies and delivery systems targeting hypoxia in the tumor microenvironment of breast cancers. In this special call we will represent an account of important physicochemical changes and signaling pathways activated in the hypoxic breast cancer microenvironments. This is then followed by various breast cancer treatment strategies, including hypoxia-sensitive signaling pathways, and approaches to develop hypoxia-targeted drug delivery systems, as well as translational approaches to pharmaceutically treating breast cancers.
This research topic invites submissions concerning but not limited to the following subject matters;
- Role of hypoxia-inducible factors in breast cancer metastasis
- The Linkage between Breast Cancer, Hypoxia, and Adipose tissue
- Breast Cancer Cells to Hypoxia: Role of AMPK/mTOR Signaling Pathway
- Hypoxia potentiates Notch signaling in breast cancer leading to decreased E-cadherin expression and increased cell migration and invasion
- Hypoxia targeting gene expression for breast cancer gene therapy
- Role of polymeric nano-encapsulated natural product in anti-cancer activity in breast cancer cells through reduction in expression of HIF-1 alpha and nuclear p65
- Role of liposomal formulation as HIF-1 alpha inhibitor for metastases of triple-negative breast cancer
- Role of polymeric nano droplets in hypoxia
- Role of Manganese Dioxide Nanoparticles therapy by Modulating Tumor Hypoxia
Important Note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
Oxygen is very important for energy metabolism, which drives cellular bioenergetics throughout our body. Precisely distributed vasculature aids in delivering oxygenated blood to all body tissues. Regions of low oxygen levels are generally termed as ‘hypoxic regions’. Hypoxia is profound in various solid tumors, as well as in myocardial infarction, some chronic renal diseases and gliomas. Rapid proliferation of a tumorous mass prevents vascularization in time, in turn leading to hypoxia in solid tumors. Low oxygen tension in tumors is found to be responsible for increased metastasis, poor patient survival, as well as drug resistance in breast cancers, as well as in cases of squamous tumors of the head and neck or cervix. Recent years have seen great progress in understanding tumor biology and of the surrounding microenvironment. Solid tumors that create regions with low oxygen levels are generally termed as being hypoxic. The creation of these hypoxic regions offer a tremendous opportunity to develop targeted therapies which can take advantage of this. Hypoxia is not merely a random by-product of cells due to uncontrolled tumor growth, rather it is a constantly evolving participant in overall tumor growth and fate.
This special issue will invite submissions which describe current trends and recent advances in drug therapies and delivery systems targeting hypoxia in the tumor microenvironment of breast cancers. In this special call we will represent an account of important physicochemical changes and signaling pathways activated in the hypoxic breast cancer microenvironments. This is then followed by various breast cancer treatment strategies, including hypoxia-sensitive signaling pathways, and approaches to develop hypoxia-targeted drug delivery systems, as well as translational approaches to pharmaceutically treating breast cancers.
This research topic invites submissions concerning but not limited to the following subject matters;
- Role of hypoxia-inducible factors in breast cancer metastasis
- The Linkage between Breast Cancer, Hypoxia, and Adipose tissue
- Breast Cancer Cells to Hypoxia: Role of AMPK/mTOR Signaling Pathway
- Hypoxia potentiates Notch signaling in breast cancer leading to decreased E-cadherin expression and increased cell migration and invasion
- Hypoxia targeting gene expression for breast cancer gene therapy
- Role of polymeric nano-encapsulated natural product in anti-cancer activity in breast cancer cells through reduction in expression of HIF-1 alpha and nuclear p65
- Role of liposomal formulation as HIF-1 alpha inhibitor for metastases of triple-negative breast cancer
- Role of polymeric nano droplets in hypoxia
- Role of Manganese Dioxide Nanoparticles therapy by Modulating Tumor Hypoxia
Important Note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
